Cegedim Dendrite expands Alliance Program three ways

Share this article:

Cegedim Dendrite has announced the expansion of its Alliance Program at the eyeforpharma Sales Force Effectiveness Europe 2009 Conference in Barcelona, Spain. 


Cegedim Dendrite is expanding formal partnerships with selected technology, software and consulting companies in order to provide additional capabilities and services to customers. Cegedim Dendrite a provider of customer relationship management solutions to the pharmaceutical industry. 


The Alliance Program will accommodate three different types of businesses.


Technology Partners are companies that offer technology and platform solutions that support and enhance the performance of Cegedim Dendrite business applications. Software Partners are companies with software products that complement Cegedim Dendrite's applications. Consulting Partners provide a range of services associated with the optimal use of Cegedim Dendrite products and services. 


Laurent Labrune, chief executive officer at Cegedim Dendrite said that an open business model —particularly partnerships with other industry leaders—fosters innovation and improved customer satisfaction. He added that Cegedim Dendrite will be building strong partnerships with other best-of-breed companies that have offerings that complement Cegedim Dendrite products and services so that the company can give its customers a technological edge in a very competitive market. 


Cegedim Dendrdite officials believe that with the open model, industry-leading solutions would be enhanced by strategic alliances which would ensure the availability of complementary products and services aimed at delivering total customer satisfaction.

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...